PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF CYSTIC FIBRIOSIS Russian patent published in 2024 - IPC A61K31/404 A61K31/443 A61K31/4439 A61K31/47 A61P11/00 

FIELD: medicine.

SUBSTANCE: group of inventions discloses a pharmaceutical composition for the treatment of cystic fibrosis, where the pharmaceutical composition contains: (a) from 15 to 250 mg of compound I; (b) a first solid dispersion containing 10 to 150 mg of compound II; and from 10 to 30 wt.% of the polymer relative to the total weight of the first solid dispersion, where the specified polymer is selected from cellulose-based polymers, polyoxyethylene-based polymers, polyethylene-propylene glycol copolymers, vinyl-based polymers, polymers based on polyethylene oxide (PEO) and polyvinyl caprolactam and polymers based on polymethacrylate; and (c) a second solid dispersion containing from 25 to 200 mg of compound III; and from 10 to 30 wt.% of the polymer relative to the total weight of the second solid dispersion, where the specified polymer is selected from cellulose-based polymers, polyoxyethylene-based polymers, polyethylene-propylene glycol copolymers, vinyl-based polymers, polymers based on polyethylene oxide (PEO) and polyvinylcaprolactam and polymers based on polymethacrylate (options). The group of inventions also relates to a tablet for the treatment of cystic fibrosis (variants), to a method for treating cystic fibrosis in a patient, and to a method for preparing a tablet (variants).

EFFECT: increasing the activity of CFTR modulation.

58 cl, 21 tbl, 15 dwg, 15 ex